Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVCN319301b
- Development stage
- Phase 1
- Lead developer
- Avicanna
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AVCN319301b is a proprietary oral capsule formulation of delta-9-tetrahydrocannabinol (THC) developed by Avicanna. It utilizes a Solid Self-Emulsifying Drug Delivery System (SEDDS) technology designed to enhance the bioavailability and absorption of the lipophilic cannabinoid compound. The drug is being evaluated in clinical trials for its acute dose-dependent physiological and subjective effects, including psychometric assessments of anxiety and mood, in healthy adults. Additionally, it is being investigated in Phase 2 trials for the management of symptoms associated with osteoarthritis.
- Other names
- Oral THC capsuleTHC SEDDS capsule
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on AVCN319301b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVCN319301b.